Full-Time

Associate Director

Biostatistics and Statistical Programming

Posted on 9/23/2025

Deadline 3/4/27
Xeris Pharmaceuticals

Xeris Pharmaceuticals

201-500 employees

Develops ready-to-use liquid-stable injectables

Compensation Overview

$140k - $240k/yr

+ Bonus + Equity

Chicago, IL, USA

Hybrid

Hybrid role; Chicago on-site required at least 3 days per week.

Category
Biology & Biotech (2)
,
Required Skills
SAS
R
Requirements
  • MS/MPH degree in biostatistics, statistics, or epidemiology
  • A minimum of six years of clinical trial experience as a statistician and/or statistical programmer in the pharmaceutical, biotech, or CRO industry
  • Experience in Phases I-III of the clinical drug development process
  • Knowledge and basic understanding of statistical concepts and techniques commonly applied to the analysis of data from clinical trials and the ability to tackle from basic to moderately complex statistical or data issues
  • Basic understanding of real-world data and observational studies.
  • SAS programming experience required, R experience is a plus
  • Working knowledge of CDISC standards
  • Prior use and implementation of sample size and power calculation software (e.g., nQuery and PASS) preferred
  • Working knowledge of Electronic Data Capture systems
  • Competencies: Attention to Detail, Organizational skills, Adaptability, Multi-Tasking, Strong Written & Verbal Communication skills, Teamwork & Collaboration, Critical Thinking, Problem Solving, Presentation Skills
Responsibilities
  • Conducts basic statistical analysis of study data with minimal supervision according to a statistical analysis plan to generate results and insights used to support study findings
  • Applies moderately advanced statistical methods, which may include simulation models and other statistical programming as needed, with guidance
  • Generates sample size and power calculations and randomizations
  • Oversees the review of statistical documents and operational activities outsourced to CROs ensuring adherence to cost, timeline, and data quality requirements to ensure that the analysis plans use the most appropriate statistical methods and that the data displays such as tables/figures/listings are accurate and complete
  • Programs or independently validates key study results to support interpretation of data
  • Provides statistical programming support to other clinical studies or regulatory submissions where another biostatistician is assigned as the sponsor lead
  • Works closely with Data Management by providing input to data management-related documents and assisting with data review and cleaning activities, as needed
  • Ensures compliance of data packages to regulatory requirements and CDISC and industry standards
  • Assists in the development of abstracts, manuscripts, presentations for scientific congresses
  • Closely collaborates and participates in knowledge sharing with other team members including non-statisticians to assist with interpretation and understanding of results
Xeris Pharmaceuticals

Xeris Pharmaceuticals

View

Xeris Biopharma Holdings develops ready-to-use, liquid-stable injectables for serious conditions, using its XeriSol and XeriJect platforms. Their products come in prefilled syringes or devices that do not require mixing or refrigeration, enabling smaller injections and quick administration. The company differentiates itself by delivering stable, ready-to-use formulations focused on rare diseases and endocrinology, supported by a U.S.-based field force and a portfolio that includes Gvoke, Keveyis, and Recorlev. Its goal is to expand access to simple, stable injectable therapies and grow its pipeline across endocrinology, neurology, and gastroenterology through its proprietary technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • Recorlev revenue nearly doubled to $50M in Q1 2026 with 60% therapy-naïve patient starts.
  • ADA 2025 Standards explicitly recommend ready-to-use glucagon formulations, validating Gvoke positioning.
  • XP-8121 Phase 3 initiation in late 2026 targets $1B–$3B peak sales by 2035.

What critics are saying

  • Eli Lilly Baqsimi captures 65% glucagon market share; Gvoke revenue flat at $20.8M Q1 2026.
  • Medicare Part D redesign favors lowest-price glucagon options, sustaining Gvoke revenue pressure indefinitely.
  • CEO Paul Edick retires August 1, 2026; leadership transition disrupts Recorlev commercial expansion momentum.

What makes Xeris Pharmaceuticals unique

  • XeriSol and XeriJect platforms enable room-temperature stable, ready-to-use injectable formulations without reconstitution.
  • Diversified rare disease portfolio: Recorlev, Gvoke, Keveyis, and Ogluo across endocrinology and neurology.
  • Achieved profitability in 2025 with $60M adjusted EBITDA and 44% revenue growth year-over-year.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma achieves profitability with $60M adjusted EBITDA, eyes 30% growth in 2026

Xeris Biopharma achieved financial self-sustainability in 2025, reporting its first full year of net income and nearly $60 million in adjusted EBITDA. The company posted 44% revenue growth, driven by its three commercial products, with Recorlev nearly doubling its patient base to approximately 700 patients. For 2026, Xeris has issued revenue guidance of $375 million to $390 million, representing over 30% growth. The company plans to initiate a Phase III trial for XP-8121 in the second half of 2026, requiring a $25 million increase in R&D spending. Xeris filed patent infringement lawsuits against two generic drug applicants to protect Recorlev patents extending to March 2040. Management maintains peak sales expectations of $1 billion for Recorlev by 2035 and $1 billion to $3 billion for XP-8121.

Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma beats Q4 estimates with $85.8M revenue, forecasts up to $390M for 2025

Chicago-based Xeris Biopharma Holdings reported fourth-quarter earnings of $11.1 million, or 6 cents per share, surpassing Wall Street expectations of 3 cents per share. Revenue reached $85.8 million, exceeding analyst forecasts of $81.4 million. For the full year, the company reported profit of $554,000 with revenue of $291.8 million. Xeris Biopharma expects full-year revenue between $375 million and $390 million. The results beat expectations across all metrics surveyed by Zacks Investment Research.

Association of Diabetes Care and Education Specialists
Aug 10th, 2025
ADCES names Katelyn O'Brien 2026 Diabetes Care and Education Specialist of the Year

I wish to extend my gratitude to those that nominated me, the ADCES Awards Committee, and Xeris Pharmaceuticals for their continued support for this award.

BioSpace
Mar 31st, 2025
Xeris Announces Changes to Its Board of Directors

The Board of Directors has appointed James Brady as a new director of Xeris' board to fill the vacancy.

ETF Daily News
Mar 29th, 2025
Cibc World Markets Corp Invests $44,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Cibc World Markets Corp invests $44,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS).

INACTIVE